BMS partners on Opdivo combo; one-quarter of insurers have signed an outcomes-based contract with a drugmaker; rebates do not lead to savings for Medicare beneficiaries
Chicago requires pharma rep to have licenses, Acorda CEO backs Califf to remain FDA commish, high-prescribing medicare docs are on the rise
A 2005 study estimated that 3.6 million people do not receive nonemergency medical care because they don't have access to transportation.
UnitedHealthcare this month launched a year-long campaign, called Hay Más Adelante.
Presidential candidate Hillary Clinton said she would go after "predatory" pharma companies in new ad spot.
An analysis by Avalere Health says 10 breakthrough therapy drugs will account for billions in spending.
Worldwide spending on cancer medications hit $100 billion last year; Bayer adds an anticoagulant to its pipeline for $100 million; GlaxoSmithKline has a new chairman
Merck said Januvia is not linked to higher heart-failure risk; Biogen plans to spend $2.5 billion on Alzheimer's disease; Mylan rejected Teva's bid
United Healthcare tests an all-in-one cancer payment model, Pfizer inks a worldwide commercialization license for a human growth factor hormone, and the Commonwealth Fund grades Medicare as the program nears its 50th.
The Office of the Inspector General says more needs to be done to keep Medicare patients from using the discount cards.
Patients have to be high-risk or Baby Boomers for coverage.
The short answer: we're not financially prepared for a slowly aging, healthy population, according to a recently published analysis.
Researchers says growth will average 5.8% a year between 2012 and 2022. They also anticipate generics will hit a leveling-off point that will drive average Rx prices upwards
The drug maker asked CMS to approve its Amyvid PET tracer for Medicare beneficiaries, but CMS declined, saying in a draft decision that widespread use would be of little value.
Good and bad news about Pradaxa; Plan B decision not deemed a big threat to Teva's sales; Study says Medicare patients more likely to receive brand-name medications than VA patients
From FDA and pharma, to Caronia and off-label communication, three healthcare policy experts offer their take on what 2013 holds in store.
The nonpartisan Congressional Budget Office is tallying medical savings differently, adding a new perspective to chatter about the financial implications of nonadherence and rising drug prices.
Nature releases the Antibodypedia's seventh generation, Elsevier adds more board review apps, and how redefining "senior" may not save money in the long run
Barack Obama edged Mitt Romney in fundraising from pharmas in the 2012 election, even as the industry favored Republicans in other contests. Were change-weary drug companies voting for the status quo?
After three years of wrangling, drug companies can again offer co-pay coupons and cards or buy doctors lunch off-site -- with some limitations.
The National Coalition on Health Care took aim at co-pay cards and coupons with a report suggesting that they might push 2 million US seniors to opt for more expensive branded drugs over generics.
Congressional Republicans -- and even a few Democrats -- are pressing the attack on the Independent Payment Advisory Board for Medicare, a part of the Affordable Care Act opposed by both PhRMA and the AMA.
Sen. Hillary Clinton unveiled her healthcare plan, promising to cover all Americans if elected president - and taking a few swipes at the pharmaceutical and insurance industries.